Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Allergen Challenge Trial of NTa53 in Allergic Conjunctivitis
jRCT2031240351Phase 3Completed
- Sponsor
- Nitto Medic
- Start
- Oct 2024
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic conjunctivitis (AC) (2 arms), sponsored by Nitto Medic. Primary endpoints: Ocular Itching Score and Conjunctival Redness Score. Started Oct 2024; status: completed.
02
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on jRCT2031240351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240351.